Show All
Practitioner
Consumer
United Kingdom Big Ben with Red Bus

Medlab Clinical receives UK Import Permission from MHRA for NanaBis™

The Medicines & Healthcare products Regulatory Agency (MHRA) has approved NanaBis™ for use in the UK Named Patient Program.

ASX Building

Important Update to Shareholders: Share Consolidation Clarification

Share consolidation has commenced, and the temporary ASX ticker is MDCDA. DA is a deferred account used whilst the shares are being consolidated. Market opening 5th Aug 2022, expectations are consolidated shares will revert back to MDC

Blue test tubes synthetic

NanaBisTM - Now With Synthetic CBD and THC

Following the company’s transformation to a pureplay biotech, Medlab Clinical has focused on the development of key asset NanaBis, a 50:50 micellar formulation of CBD and THC, in the treatment of cancer-induced bone pain.

graphs and images showing investor data on a screen for stock market

Medlab proposes DUAL LISTING to the U.S. Nasdaq Stock Market

Medlab Clinical Ltd (ASX:MDC) welcomes all shareholders to exercise their voting rights at Extraordinary General Meeting scheduled for 28th July 2022.

9 bottles of Vitamins made by Medlab

Medlab signs exclusive commercial agreement for 12 products with YesHealth

YesHealth (Malaysia) signs 5-year exclusive distribution rights for the Medlab branded nutraceutical (VMS) lines in Malaysia, Vietnam, and (Non-Exclusive) Singapore.

9 bottles of Vitamins made by Medlab

Medlab Clinical Signs NRGBiotic (Depression Product) Deal with Cultech Limited

Cultech Limited (UK) signs 3-year trade deal for NRGBiotic to enter UK pharmacies and Health food stores with optionality for European and US expansion

Blue background with white digital symbols over it

Transforming into a pure-play biotech

With lead product NanaBis™ (NanoCelle® encapsulated 50:50 THC:CBD for pain) preparing to enter a Phase III trial in pain, management has decided to fully focus on therapeutics development and divested its nutraceuticals portfolio

RNA

Government grant to apply NanoCelle® to an RNA nasal vaccine

Medlab (ASX:MDC) receives Government grant to apply NanoCelle® to an RNA nasal vaccine in collaboration with University of NSW (UNSW) and Macquarie University (MQ) to fight COVID-19 future potential epidemics.

phone with a share graph on it

Global Investor News March 2022

Bimonthly Medlab news. This month: a note from our CEO, a research note from Morgan’s and UK NanaBis and NanoCBD.

Medlab Clinical Ltd (ASX:MDC) sells its Australian nutraceutical business to PharmaCare

We are pleased to announce the sale of the Australian-only part of its nutraceutical business to PharmaCare

Annual Message to Shareholders October 2021

Once Medlab Clinical’s listing on the ASX six years ago its experienced team of scientists have made extraordinary advances in the creation and manufacture of unique, world-leading products and valuable intellectual property.

Scientists with virtual reality glasses - Medlab Clincial

Medlab mixes reality with Microsoft

Read the three featured stories from Microsoft about Medlab's adoption of mixed reality solutions including HoloLens 2 head-mounted devices with Dynamics 365